Evaluation Protocol for SARS-CoV-2 Serological Assays.

Gededzha, Maemu P; Jugwanth, Sarika; Mampeule, Nakampe; Zwane, Nontobeko; David, Anura; Scott, Lesley; Stevens, Wendy; Mayne, Elizabeth S

Gededzha, Maemu P; Jugwanth, Sarika; Mampeule, Nakampe; Zwane, Nontobeko; David, Anura; Scott, Lesley; Stevens, Wendy; Mayne, Elizabeth S.

Afiliação

Gededzha MP; Department of Immunology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Maemu.gededzha@nhls.ac.za.
Jugwanth S; National Health Laboratory Services, Johannesburg, South Africa. Maemu.gededzha@nhls.ac.za.
Mampeule N; Department of Immunology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Zwane N; National Health Laboratory Services, Johannesburg, South Africa.
David A; Department of Immunology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Scott L; National Health Laboratory Services, Johannesburg, South Africa.
Stevens W; Department of Immunology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Mayne ES; National Health Laboratory Services, Johannesburg, South Africa.

Methods Mol Biol ; 2511: 307-319, 2022.

Article em En | MEDLINE | ID: mdl-35838970

Assuntos

COVID-19; SARS-CoV-2; Anticorpos Antivirais; COVID-19/diagnóstico; Teste para COVID-19; Humanos; Imunoensaio/métodos; Sensibilidade e Especificidade

Palavras-chave

Automated serology Platform; Lateral flow immunoassay; Precision; SARS-CoV-2 serology test

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Diagnostic_studies / Guideline / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google